Aspirin is not a primary treatment for pulmonary embolism, but it does play a meaningful supporting role in specific situations. Standard treatment for a pulmonary embolism (PE) relies on anticoagulants, which are far more effective at dissolving and preventing blood clots in the veins and lungs. Aspirin’s value shows up mainly after initial treatment ends, as a way to reduce the chance of a clot coming back, and there is emerging evidence it may also influence how severe an acute PE episode is.
Why Aspirin Isn’t First-Line Treatment
Pulmonary embolism is caused by a blood clot that travels to the lungs, and venous clots form differently than the arterial clots aspirin is best known for treating. Arterial clots (the kind behind heart attacks and strokes) are heavily driven by platelets clumping together. Venous clots are primarily made of fibrin, white blood cells, and red blood cells, with platelets playing a smaller role. That’s why they appear red rather than the pale “white” clots seen in arteries.
Aspirin works by permanently blocking an enzyme that helps platelets stick together. This makes it powerful against arterial clots but weaker against the fibrin-heavy clots that cause PE. Anticoagulants target the clotting cascade itself, directly reducing fibrin formation, which is why they remain the standard of care. In head-to-head comparisons, anticoagulants like apixaban and rivaroxaban reduced recurrent clot risk by roughly 73% more than aspirin did.
What Aspirin Does After Treatment Ends
Where aspirin has the clearest evidence is in secondary prevention: reducing the chance of another clot after you’ve finished a course of anticoagulant therapy. Most patients with an unprovoked PE (one without an obvious trigger like surgery or immobilization) take anticoagulants for 6 to 18 months. Once that treatment stops, the risk of recurrence climbs back up.
Two major clinical trials, WARFASA and ASPIRE, tested whether low-dose aspirin could fill that gap. In the combined analysis published in the New England Journal of Medicine, patients who took aspirin after finishing anticoagulation had a recurrence rate of 4.8% per year compared to 6.5% per year on placebo. That translates to about a 26% reduction in recurrent clots. When researchers looked at a broader outcome that included heart attack, stroke, and cardiovascular death alongside clot recurrence, aspirin cut the combined risk by 34%, dropping the annual rate from 8.0% to 5.2%.
These results position aspirin as a reasonable option for people who have completed their anticoagulant course and face a choice between taking nothing, restarting anticoagulants (with their higher bleeding risk), or using aspirin as a middle ground. Current guidelines recognize aspirin as an option for extended prevention specifically in patients who refuse or cannot tolerate ongoing anticoagulant therapy.
Aspirin Before a PE Happens
A newer line of research suggests that people who are already taking aspirin for other reasons (typically heart disease) may fare better if they develop a pulmonary embolism. A retrospective study published in the World Journal of Cardiology found that patients who were on aspirin before being hospitalized for acute PE had significantly lower rates of right ventricular strain, intensive care admission, shock, and in-hospital death compared to those not on aspirin.
This doesn’t mean aspirin prevents PE outright or should be started in anticipation of one. The finding likely reflects aspirin’s ability to dampen inflammation and interfere with certain clotting pathways beyond just platelet aggregation. Aspirin appears to reduce tissue factor expression, limit thrombin formation, and promote more efficient breakdown of fibrin. These effects are modest compared to full anticoagulation, but they may blunt the severity of a clot event if one occurs.
This research is still observational, not the gold standard of randomized trials, so it’s not yet the basis for treatment recommendations.
How Aspirin Compares to Anticoagulants
The comparison is not close when it comes to preventing recurrent clots. A network meta-analysis found that apixaban at a low dose and rivaroxaban each reduced recurrence risk by about 73% compared to aspirin, and older blood thinners like warfarin reduced it by roughly 80%. Aspirin is simply not as effective at stopping venous clots from forming again.
The trade-off is bleeding risk. Anticoagulants carry a higher chance of serious bleeding, which is why doctors don’t always keep patients on them indefinitely. Aspirin causes less major bleeding, making it a safer long-term option for patients whose clot risk is moderate rather than high. The clinical trials that tested aspirin for recurrence prevention reported low rates of major bleeding, which is one reason guidelines include it as an alternative for select patients.
Dosing for Clot Prevention
The major PE prevention trials used low-dose aspirin, typically 100 mg daily (close to the 81 mg dose commonly sold in the United States). Research on aspirin dosing for cardiovascular prevention, including the large ADAPTABLE trial of over 15,000 patients, found no meaningful difference in effectiveness or bleeding risk between 81 mg and 325 mg daily. Both doses performed similarly. For clot prevention after PE, low-dose aspirin is the standard choice.
Who Benefits Most From Aspirin After PE
The strongest evidence applies to a specific group: people who had a first unprovoked pulmonary embolism, completed 6 to 18 months of anticoagulant therapy, and are deciding what to do next. For these patients, aspirin offers a modest but real reduction in recurrence compared to stopping all preventive treatment. It’s not a replacement for anticoagulants during the initial treatment period, and it’s not the best option for people at very high risk of recurrence, where continued anticoagulation is typically preferred.
For people whose PE had a clear, temporary trigger (like major surgery, a long flight, or a leg cast), the recurrence risk after completing anticoagulation is already lower, and the benefit of adding aspirin is less certain. The trial evidence is strongest for unprovoked clots, where the underlying cause is unclear and the long-term risk remains elevated.